Overview

Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease

Status:
Terminated
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
Examine the effects of TI in combination with an anti-diabetic regimen including inhaled insulin versus anti-diabetic treatment without inhaled insulin on lung function & pulmonary safety
Phase:
Phase 3
Details
Lead Sponsor:
Mannkind Corporation
Sanofi
Collaborator:
Mannkind Corporation
Treatments:
Hypoglycemic Agents
Insulin
Insulin, Globin Zinc